Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
Groundbreaking HIV vaccine's effects were real – and could be made to work better

Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV

Published
13 November 2014
By
Gus Cairns
What are the barriers that could stop HIV treatment becoming HIV prevention?

One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy

Published
12 November 2014
By
Gus Cairns
Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial

There was widespread misunderstanding and misinterpretation of questions about anal sex being asked of participants in the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial,

Published
10 November 2014
By
Lesley Odendal
D-day for The Pill for HIV

The media coverage of the unexpectedly early success of two trials of pre-exposure prophylaxis - PrEP - has generally been positive, sometimes overly so. But I haven't seen anything that actually explains why the results of the PROUD and IPERGAY studies are so important, or why they represent a gear-change in the accelerating race towards the end of HIV.

Published
05 November 2014
From
Huffington Post
NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

Published
05 November 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
High effectiveness seen in English PrEP trial

The Steering Committee* of the PROUD trial of pre-exposure prophylaxis (PrEP) in gay men in England announced today that participants currently on the deferred arm of the

Published
16 October 2014
By
Gus Cairns
Advocates Applaud Launch of MTN-017, World’s First Phase II Rectal Microbicide Study

IRMA applauds the launch of the world’s first-ever Phase II rectal microbicide trial. The Microbicide Trial Network’s study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

Published
02 October 2014
From
IRMA
New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

Published
09 September 2014
From
HIVandhepatitis.com
Racial/ethnic disparities in HIV medical studies examined by researchers

Social/behavioral intervention vastly increased the number of African American and Latino individuals living with HIV/AIDS who enrolled in HIV/AIDS medical studies, a study has found. Nine out of 10 participants who were found eligible for studies decided to enroll, compared to zero participants among a control group.

Published
08 July 2014
From
Science Daily
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

Published
06 June 2014
From
Merck
← First12345...12Next →

Filter by country